Rein Therapeutics (RNTX) Current Assets (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Current Assets of $5.5 million for Q1 2026, down 34.55% year-over-year from $8.3 million in Q1 2025, and up 26.05% quarter-over-quarter from $4.3 million in Q4 2025.
Rein Therapeutics (RNTX) Current Assets (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Current Assets for 11 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 34.55% year-over-year to $5.5 million; the TTM figure through Mar 2026 stood at $5.5 million (down 34.55% YoY), while the FY2025 annual figure was $4.3 million, down 68.32% from the prior year.
- Current Assets climbed to $5.5 million in Q1 2026 per RNTX's latest filing, from $4.3 million in the prior quarter.
- Across five years, Current Assets topped out at $40.0 million in Q1 2022 and bottomed at $4.3 million in Q4 2025.
- Historically, Current Assets has averaged $16.6 million across 5 years, with a median of $14.0 million in 2023.
- Annual changes were most pronounced in 2024 — Current Assets soared 65.99% — and 2025, when it slumped 72.31%.
- Rein Therapeutics' Current Assets stood at $21.9 million in 2022, then retreated by 16.49% to $18.3 million in 2023, then slipped by 25.23% to $13.7 million in 2024, then slumped by 68.32% to $4.3 million in 2025, then rose by 26.05% to $5.5 million in 2026.
- Business Quant data shows RNTX's Current Assets at $5.5 million in Q1 2026, $4.3 million in Q4 2025, and $5.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 1.76 Bn |
| 10 | Rein Therapeutics | 54.88 Mn | 54.88 Mn | - | 41.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.45 Mn |
| Mar 31, 2026 | 5.45 Mn |
| Dec 31, 2025 | 4.33 Mn |
| Sep 30, 2025 | 5.17 Mn |
| Jun 30, 2025 | 6.60 Mn |
| Mar 31, 2025 | 8.33 Mn |
| Dec 31, 2024 | 13.66 Mn |
| Sep 30, 2024 | 18.68 Mn |
| Jun 30, 2024 | 23.16 Mn |
| Mar 31, 2024 | 12.76 Mn |
| Dec 31, 2023 | 18.27 Mn |
| Sep 30, 2023 | 12.79 Mn |
| Jun 30, 2023 | 13.95 Mn |
| Mar 31, 2023 | 17.11 Mn |
| Dec 31, 2022 | 21.87 Mn |
| Sep 30, 2022 | 27.05 Mn |
| Jun 30, 2022 | 33.55 Mn |
| Mar 31, 2022 | 39.99 Mn |
| Dec 31, 2021 | 48.18 Mn |
| Sep 30, 2021 | 54.42 Mn |